Impact of Smoking on Clinical Outcomes in ST-Elevated Myocardial Infarction Patients with Small Infarct Related Coronary Vessels

Yıl 2020, Cilt: 10 Sayı: 1, 121 - 127, 16.03.2020

Kahraman Coşansu Mustafa Çağın Üreyen

https://doi.org/10.31832/smj.637410

Öz

Objective: In
the literature, there is no data for the comparative efficacy of smoking status
in ST-segment elevation myocardial infarction(STEMI) patients with small vessel
coronary artery disease(CAD) on clinical outcomes.The aim of this study was to
evaluate the in-hospital mortality and long-term outcomes of STEMI patients
with small vessel coronary artery disease according to smoking status.

Materials and Methods: Between
January 2014 and May 2017,388 consecutive STEMI patients with small vessel CAD
were included in this retrospective study.The patients were classified into two
groups according to status of smoking, as smokers (n =181) and non-smokers (n =207).The
primary outcome was major adverse cardiac events(MACE).The secondary end-point
included in-hospital mortality.

Results: During the follow-up
of 24 months, MACE occurred in 25(14.1 %) patients in smokers and 12(6.3 %)
patients in non-smokers(p: 0.014).The target-lesion revascularization(TLR), target-vessel
revascularization(TVR) and myocardial infarction(MI) rates was found
significantly higher in the smoker group as compared with the non-smoker
group(p: 0.049, p: 0,012, p: 0,025, respectively).The rate of in-hospital
mortality was found significantly lower in smokers (p: 0.04).In multivariate
Cox analysis for 2-year MACE, after accounting for all covariables, no-smoking
was associated with 58% decreased risk in the small vessel CAD population (HR:
0.42, 95% CI: 0.21-0.84).Moreover, no-smoking was associated with a decreased
TLR (HR: 0.38, 95% CI: 0.14-0.99),TVR (HR:0.31, 95% CI: 0.12-0.79) and MI(HR:
0.41, 95% CI: 0.19-0.89) risk at 2-years follow up.

Conclusions: In
our real-world registry of patients who underwent primary percutaneous coronary
intervention(PPCI),smokers had lower in-hospital mortality,but poorer outcomes
during 2-year follow-up. 

Anahtar Kelimeler

Primary percutaneous coronary intervention; ST elevation myocardial infarction; smoking status; small vessel coronary artery.

İnfarktla İlişkili Küçük Koroner Damarları Olan ST-Yükselmeli Miyokard İnfarktüslü Hastalarda Sigara İçiminin Klinik Sonuçlar Üzerine Etkisi

Öz

Amaç: Literatürde ST-segment yükselmeli miyokard infarktüsünde(STEMI) sigara
içimi durumunun, küçük damar koroner arter hastalığı(KAH) olan hastalarda
klinik sonuçlar üzerinde karşılaştırmalı etkinliği konusunda veri yoktur.
Bu çalışma, STEMI ile başvuran küçük damar koroner
arter hastalığı olan hastaların sigara içip içmemesine göre   hastane içi mortalite ve uzun dönem
sonuçlarını değerlendirmeyi amaçlamıştır.

Gereç ve Yöntemler: Bu retrospektif çalışmaya Ocak 2014 ve Mayıs 2017
arasında, küçük damar KAH olan 388 ardışık STEMI hastası dahil edildi. Hastalar sigara içme durumuna göre sigara içenler (n=181)
ve sigara içmeyenler (n=207) olarak iki gruba ayrıldı. Birincil son nokta majör
olumsuz kardiyak olaylar (MACE) idi. İkincil son nokta hastane içi mortaliteyi
içeriyordu.

Bulgular: 24 aylık takipte sigara içenlerde 25(%14,1) hastada,
sigara içmeyenlerde 12(%6,3) hastada MACE gelişti(p:0,014). Sigara içen grupta hedef lezyon revaskülarizasyonu(TLR),
hedef damar revaskülarizasyonu(TVR) ve miyokard infarktüsü(MI) oranları sigara
içmeyenlere göre anlamlı derecede yüksek bulundu Sırasıyla (p:0.049, p:0,012,
p:0,025). Hastane içi mortalite oranı
sigara içenlerde anlamlı derecede düşük bulundu (p: 0.04). 2 yıllık MACE için çok değişkenli Cox analizinde,
tüm değişkenler için hesap yapıldıktan sonra, sigara içilmemesi, küçük damar
KAH popülasyonunda %58 oranında azalmış risk ile ilişkili bulunmuştur (HR:
0.42, %95 CI: 0.21-0.84). Ayrıca sigara içilmemesi 2 yıllık takipte, TLR (HR:
0.38, %95 CI: 0.14-0.99), TVR (HR: 0.31, %95 CI: 0.12-0.79) ve MI (HR: 0.41, %95
CI: 0,19-0,89) için daha düşük bir risk ile ilişkilendirildi.

Sonuç: Gerçek yaşam kayıt çalışmamızda
primer perkutan koroner girişim (PPKG) yapılan küçük
damar KAH olan hastalarda sigara içenlerin
hastane içi ölüm oranları daha düşük saptandı, ancak 2 yıllık takipte daha kötü
sonlanımları vardı.

Anahtar Kelimeler

Primer perkütan koroner girişim; ST yükselmeli miyokard infarktüsü; sigara içme durumu; küçük damar koroner arter.

Kaynakça

• 1. R. Doll, R. Peto, J. Boreham, I. Sutherland. Mortality in relation to smoking: 50 years' observations on male British doctors. J Epidemiol Community Health. 2004; 58: 930.
• 2. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol. 1993; 3:417-424.
• 3. M.M. Rahman, I. Laher. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol. 2007; 5:276-92.
• 4. D. Himbert, M. Klutman, G. Steg, K. White, D.C. Gulba. Cigarette smoking and acute coronary syndromes: a multinational observational study. Int J Cardiol. 2005; 100:109-117.
• 5. Serrano M, Madoz E, Ezpeleta I, San Julián B, Amézqueta C, Pérez Marco JA, et al. Smoking cessation and risk of myocardial reinfarction in coronary patients: a nested case-control study. Rev Esp Cardiol. 2003; 56:445-451.
• 6. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al. Clinical implications of cigarette smoking in acute myocardial infarction: acute angiographic findings and long-term prognosis. Am Heart J. 1997; 134:955-960.
• 7. Grines CL, Topol EJ, O'Neill WW, George BS, Kereiakes D, Phillips HR, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation. 1995; 91:298-303.
• 8. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995; 26:1222-1229.
• 9. Rakowski T, Siudak Z, Dziewierz A, Dubiel JS, Dudek D. Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Thromb Thrombolysis. 2012; 34: 397–403.
• 10. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, et al. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002; 13:133-9.
• 11. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998; 32:1610-8.
• 12. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and longterm outcome after coronary stent placement. Circulation 1998; 98:1875–80.
• 13. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45:1193–1200.
• 14. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:529-555.
• 15. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012; 60:1581–1598.
• 16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344-2351.
• 17. Keane D, Azar AJ, de Jaegere P, Rutsch W, de Bruyne B, Legrand V, et al. Clinical and angiographic outcome of elective stent implantation in small coronary vessels: an analysis of the BENESTENT trial. Semin Interv Cardiol 1996; 1:255-62.
• 18. Gao R, Abizaid A, Banning A, Bartorelli AL, Džavík V, Ellis S, et al. One-year outcome of small-vessel disease treated with sirolimus-eluting stents: a subgroup analysis of the e-SELECT registry. J Interv Cardiol. 2013; 26:163-172.
• 19. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43:1731–7.
• 20. Aune E, Røislien J, Mathisen M, Thelle DS, Otterstad JE. The "smoker’s paradox" in patients with acute coronary syndrome: a systematic review. BMC Med 2011; 9:97.
• 21. Ciccarelli G, Barbato E, Golino M, Cimmino G, Bartunek J, Di Serafino L, et al. Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. J Interv Cardiol. 2017; 30:5-15.
• 22. Symons R, Masci PG, Francone M, Claus P, Barison A, Carbone I, et al. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker's paradox revisited. Eur Heart J.2016; 37:2756-2764.
• 23. Reinstadler SJ, Eitel C, Fuernau G, de Waha S, Desch S, Mende M, et al. Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging. 2017; 18:39-45.